Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 8/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7659544 | 0.88 | GAA (0.54) | — | |
| SCHEMBL6744961 | 0.83 | CTSS (0.48) | CTSSCTSKCTSBCTSL | |
| SCHEMBL5532239 | 0.83 | CTSS (0.46) | STSCTSSCTSKCTSBCTSL | |
| SCHEMBL6741766 | 0.82 | CTSS (0.60) | CTSSCTSKCTSBCTSL | |
| SCHEMBL6742147 | 0.82 | CTSS (0.51) | STSCTSSCTSKCTSBCTSL | |
| SCHEMBL6744250 | 0.81 | ALDH1A1 (0.52) | CTSLKDM4EPKM | |
| SCHEMBL6742151 | 0.78 | STS (0.47) | STSGPR119P2RX7KDM4EPKM | |
| SCHEMBL5532237 | 0.76 | CTSS (0.53) | CTSSCTSKCTSBCTSL | |
| SCHEMBL15515225 | 0.75 | KDM4E (0.63) | STSGPR119KDM4EPKMACHE | |
| SCHEMBL6061910 | 0.73 | CTSL (0.56) | CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | STS 885/4885CTSS 1/4885CTSK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.